Validation and implementation of ambulatory obstructive sleep apnea polygraphy screening combined with wearable semi-continuous heart rhythm monitoring in patients with atrial fibrillation: a validation and a pilot study - Scorecard - MDSpire
Advertisement
Validation and implementation of ambulatory obstructive sleep apnea polygraphy screening combined with wearable semi-continuous heart rhythm monitoring in patients with atrial fibrillation: a validation and a pilot study
Clinical Scorecard: Assessment and Application of Polygraphic Screening for Ambulatory Obstructive Sleep Apnea Alongside Wearable Continuous Heart Rhythm Monitoring in Atrial Fibrillation Patients: A Validation and Pilot Investigation
At a Glance
Category
Detail
Condition
Obstructive Sleep Apnea (OSA)
Key Mechanisms
Polygraphic screening and heart rhythm monitoring
Target Population
Patients with Atrial Fibrillation (AF)
Care Setting
Ambulatory care
Key Highlights
NOX-T3s demonstrated good diagnostic performance for detecting moderate-to-severe OSA (AUC 0.83 simultaneous; 0.80 home)
An optimized AHI cut-off of 11.1 events/h improved NOX-T3s accuracy (0.85), with sensitivity of 92.9% and specificity of 75.0%
OSA screening was successful in 97.1% of patients, identifying moderate-to-severe OSA in 79.3%
Semi-continuous smartwatch-based rhythm monitoring was successful in 96.6%, detecting 6.7 times more AF episodes compared to spot-check alone
High patient comfort reported for both NOX-T3s and rhythm monitoring devices
Guideline-Based Recommendations
Diagnosis
Use of cardiorespiratory polygraphy (PG) devices for OSA screening in AF patients
Management
Referral for polysomnography (PSG) for patients screening OSA-positive
Monitoring & Follow-up
Integration of semi-continuous heart rhythm monitoring with wearable technology
Risks
Untreated OSA may lead to poor response to AF treatment and increased risk of AF recurrence
Patient & Prescribing Data
Remove unsupported claims about CPAP treatment reducing AF recurrence.
In a nationwide Finnish cohort, patients with atrial fibrillation and gout had higher ischemic stroke rates, while urate-lowering therapy was associated with lower stroke rates.
